| Literature DB >> 31616403 |
Sachin Kumar1, Madhu Dikshit2.
Abstract
Neutrophils are the most abundant, short lived, and terminally differentiated leukocytes with distinct tiers of arsenals to counter pathogens. Neutrophils were traditionally considered transcriptionally inactive cells, but recent researches in the field led to a paradigm shift in neutrophil biology and revealed subpopulation heterogeneity, and functions pivotal to immunity and inflammation. Furthermore, recent unfolding of metabolic plasticity in neutrophils has challenged the long-standing concept of their sole dependence on glycolytic pathway. Metabolic adaptations and distinct regulations have been identified which are critical for neutrophil differentiation and functions. The metabolic reprogramming of neutrophils by inflammatory mediators or during pathologies such as sepsis, diabetes, glucose-6-phosphate dehydrogenase deficiency, glycogen storage diseases (GSDs), systemic lupus erythematosus (SLE), rheumatoid arthritis, and cancer are now being explored. In this review, we discuss recent developments in understanding of the metabolic regulation, that may provide clues for better management and newer therapeutic opportunities for neutrophil centric immuno-deficiencies and inflammatory disorders.Entities:
Keywords: TCA cycle; diseases; fatty acid oxidation; glutaminolysis; glycolysis; metabolic adaptation; neutrophil functions; pentose phosphate pathway
Year: 2019 PMID: 31616403 PMCID: PMC6764236 DOI: 10.3389/fimmu.2019.02099
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Overview of key metabolic pathways in neutrophils. Glycolysis is a major metabolic pathway in neutrophil cytosol, which converts glucose to pyruvate through a series of enzymes and reaction. In the absence of oxygen through anaerobic glycolysis, pyruvate gets reduce to lactate, and secreted out. While in the presence of oxygen, pyruvate participates in TCA cycle by its conversion to acetyl-coenzyme A (acetyl Co A) that provides reducing energy intermediates NADH and FADH2 which trough ETC generate ATPs. Neutrophils also utilize additional pentose-phosphate pathway (PPP) by using glucose-6-phosphate, an intermediate of the glycolytic pathway, as an entry point and using oxidative and non-oxidative phases produce NADPH and riboses that subsequently generate nucleotides. NADPH is critical as key NADPH oxidase dependent ROS generation in neutrophils and also regulates redox signaling. Depending on glucose abundance, glycogen stores get enriched in neutrophils that on-demand provides glucose based glycolytic intermediate supply. TCA cycle intermediate citrate through fatty acid synthesis (FAS) can lead to the generation of free fatty acid, while these endogenous FFA or transported from the extracellular environment through FAO pathway yields acetyl-CoA that fuels TCA cycle and produce significantly more energy in form of ATPs. Glutamine through glutaminolysis produces α-ketoglutarate and thus supports the TCA cycle. In addition, neutrophils also utilize glycerol-3- phosphate shuttle to generate NAD+ from NADH and helps in maintaining mitochondrial membrane potential. ATP, adenosine triphosphate; ETC, electron transport chain; FAO, fatty acid oxidation; NADPH, the reduced form of nicotinamide adenine dinucleotide phosphate; ROS, reactive oxygen species.
Key metabolic pathways regulating distinct neutrophil functions.
| Differentiation | FAO, TCA, OxPHOS | During differentiation, Glycolysis & autophagy decline. Modulation of FAO, TCA, and mitochondrial respiration regulate neutrophil differentiation. | ( |
| Energetics | Glycolysis | Neutrophil ATP level completely abolishes by glycolysis inhibitors, While remains insensitive to mitochondrial respiratory chain inhibitors | ( |
| Phagocytosis | Glycolysis | Glycolytic inhibitors completely diminish neutrophil phagocytic functions. | ( |
| ROS/RNS | PPP, ETC (complex I, III) | PPP potentiates ROS by providing NADPH, a substrate of NADPH Oxidase, while complex I and III inhibition cause generation of mitochondrial ROS. | ( |
| NETs | Glycolysis and PPP | Glucose uptake increases during NETosis and Glycolysis (2-DG) and PPP (6-AN) inhibitors mitigate NETs formation | ( |
| Chemotaxis | Mitochondria, Purinergic signaling | ATP and purinergic signaling at front governs neutrophils chemotaxis. Mitochondria with high Δψm localize at front & promote purinergic signaling. FCCP blocks chemotaxis. | ( |
| Apoptosis | Mitochondria | Mitochondria function as redox, Ca2+ sensor. Defective Δψm initiates release of proapoptotic factors into the cytoplasm and cause apoptosis. | ( |
6-AN, 6-amino-nicotinamide; ATP, Adenosine triphosphate; 2-DG, 2-deoxy-glucose; Ca.
Summary of distinct genes/proteins involved in metabolism and regulating neutrophil functions.
| AK2 | Regulates the energy metabolism in mitochondria through homeostasis of adenine nucleotides | shRNA induced knock-down of adenylate kinase 2 | Blocked granulocyte differentiation, elevated glucose consumption but abrogated mitochondrial metabolism | ( |
| NAMPT | Essential enzyme for NAD+ biosynthesis, maintain TCA and FAO pathways | NAMPT and its substrate vitamin B3 (nicotinamide) treatment | Induced granulocytic differentiation of CD34+ and HL-60 cells | ( |
| Atg5 | Involved in autophagosome formation, down products provide inputs to cellular metabolism and energetics | Atg5fl/fl-Lyz2Cre/Cre mice, ShRNA-KnockdownAtg5flox/flox-Lyz2Cre/Cre mice | Increased proliferation rate in the neutrophil precursor cells and neutrophilia | ( |
| Atg7 | Essential for Autophagy, provides free fatty acids | Vav-cre 3 Atg7f/f, | Reduced neutrophil differentiation | ( |
| FAS | Involved in lipogenesis | Dramatic loss of neutrophils due to apoptosis | ( | |
| PexRAP | Terminal step enzyme in ether lipid synthesis | Inducible Knockout using | Leukopenia with loss of neutrophils | ( |
| GPR43/ FFAR2 | Receptor for short-chain fatty acids | Constitutive free fatty acid receptor 2 deficient mice | Reduced neutrophil recruitment, high susceptibility to inflammation | ( |
| G6PD | Regulate switch of glycolysis toward pentose phosphate pathway, causes NADPH dependent depletion of glutathione | G6PD deficient patientsG6PD-deficient mutant (G6PDmut) mice | Defects in ROS generation and NETosis with induced susceptibility to infection Hematopoietic G6PDmut exhibited improved glucose tolerance, insulin sensitivity with low FFAs | ( |
| G6pc3 | Glucose-6-phosphatase- β that hydrolyzes glucose-6-phosphate | Patient with G6Pase-β deficiency | Severe congenital neutropenia | ( |
| polg | Mitochondrial DNA polymerase regulates OXPHOS | CRISPR/Cas9 mediated neutrophil-specific knockout in Zebra fish | Reduced the velocity of neutrophil interstitial migration | ( |
| SDH | Involved in TCA cycle and ETC | Patients with mutations in sdh | Reduced constitutive apoptosis | ( |
| Pdh2 | Regulates glycolytic flux and glycogen stores | Phd2fl/fl LysM-Cre (myeloid-specific loss of Phd2) | Increased neutrophil activation, motility, functional capacity, and survival due to enhanced glycolytic capacity, intracellular ATP, and glycogen | ( |
| HIF-1a | Oxygen sensing and glycolytic flux | Deletion of HIF-1α using LysM-Cre | Defective glycolysis and ATP generation. Low expression of granule proteases, decline in antimicrobial activity, and survival | ( |
| mTOR | Energy and nutrient sensor, regulates Glycolysis, OxPHOS, and Autophagy | ShRNA mediated knockdown of mTOR complex proteins, pharmacological inhibition | Inhibits neutrophil chemotaxis, differentiation, and NETosis | ( |
AK2, adenylate kinase 2; Atg5, Autophagy related 5; Atg7, Autophagy related 7; ATP, Adenosine triphosphate; FAO, Fatty acid oxidation; FAS, Fatty acid synthase; G6Pase-β, Glucose-6-phosphatases- β; G6PD, Glucose-6-phosphate dehydrogenase; GPR43/FFAR2, G-protein coupled receptor 43; HIF-1α, Hypoxia-inducible factor-1α; mTOR, Mammalian target of rapamycin; NAD, Nicotinamide dinucleotide; NAMPT, Nicotinamide phosphor-ribosyltransferase; OxPHOS, Oxidative phosphorylation; Pdh2, Prolyl hydroxylase 2; PexRAP, Peroxisomal Reductase Activating PPAR; polg, Mitochondrial DNA polymerase gamma; PPAR, Peroxisome proliferator-activated receptor; SDH, Succinate dehydrogenase; TCA, Tricarboxylic acid cycle.
Figure 2Regulation of neutrophil metabolism. Neutrophil utilizes distinct metabolic pathways including glucose oxidation, glycogen breakdown and β-oxidation of fatty acids. After transport of glucose in the cytosol, hexokinase converts it to G6P that participate in different pathways like glycolysis, PPP, glycogen synthesis, or ER cycling. Glycolysis converts glucose to pyruvate that can further utilize in TCA cycle or forms lactate. G6PT and G6Pase regulate recycling of G6P in ER and disruption of glucose/G6P balance and ER stress due to G6PT or G6Pase-β deficiencies result in impaired energy homeostasis, functions, and survivals of neutrophils. While FFA gets transport to the cytosol and autophagy also release FFA that undergoes β-oxidation and provides a high level of ATPs through mitochondrial OxPHOS pathway and regulates neutrophil differentiation. On the other hand, in neutrophils FAS and PexRAP produce peroxisomal lipids that get incorporated into the plasma membrane and thus maintaining membrane integrity and viability. Mitochondrial OxPHOS provides ATPs that also drives purinergic signaling in neutrophils. Transcriptional regulator HIF-1α regulates glucose transport as well as enzymes involved in the glycolysis. HIF-1α regulates PPARy, that also increases glucose uptake and regulates fatty acid metabolism. Interestingly, over-activation of PPARy in diverse diseases leads to defective energetics and functions of neutrophils. mTOR functions as a master regulator of mitochondrial metabolism and also regulates purinergic signaling. AMPK that senses AMP-ATP levels also controls neutrophil metabolism and functions.
Metabolic alteration responsible for neutrophil dysfunctions in disease conditions.
| Sepsis | Altered cellular bioenergetics mitochondrial and FAO pathways and atypical metabolic milieu | Paralysis of neutrophil migration and functions | Targeting PPAR-γ and purinergic signaling reversed neutrophil chemotaxis defects | ( |
| Diabetes | Diminished G6PD and glutaminase activities, high FFA and triacylglycerols, depolarized mitochondrial potential, and low ATP due to defective autophagy | Adhesion, chemotaxis, phagocytic, ROS production, and microbicidal defects | Insulin and metformin protected some of neutrophil functions | ( |
| Excessive free glucose and amino acids, elevated mTOR signaling | Impaired degranulation and phagocytosis functions | Increase mTOR, Glut1 and PiT1, functional reprogramming with decreased intracellular glutathione | ( | |
| G6PT deficiency, Disturbed glucose homeostasis with defective glucose uptake and reduced levels of G6P, lactate, ATP and NADPH | Neutropenia and neutrophil Neutropenia and neutrophil, respiratory burst | Unregulated HIF-1α and activated PPAR-γ pathway, PPARγ antagonist rescued neutrophil dysfunctions | ( | |
| G6Pase-β deficiency | Impaired energy homeostasis with low glucose uptake and G6P levels, enhanced ER/ mitochondrial stress | Severe congenital neutropenia due to increased apoptosis, Defective superoxide, chemotaxis, calcium flux | G-CSF rescues neutrophil defects by inducing glucose uptake and energetics | ( |
| Disturbed glycolysis and mitochondrial oxidative metabolism | Impaired phagocytosis and oxidative burst with increased NETosis and cell death | Altered regulation of mTORC1, AMPK, PPARy | ( | |
| Rheumatoid arthritis | Altered glucose metabolism | Delayed apoptotic, increased in cytokines spontaneous NETosis | Unregulated PPAR-γ in monocytes is defined, neutrophils? | ( |
| Atherosclerosis | Metabolic disturbance hyperlipidemia and hypercholesterolemia | Reduced neutrophil recruitment, high susceptibility to inflammation | Reduce neutrophil infiltration by inhibition of NAMPT enzyme | ( |
| G6PD deficiency | Compromised PPP metabolism, decrease in NADPH, depletion of glutathione | Defective superoxide generation, NETosis and microbicidal activity | Neutrophil functions depend on severity of G6PD deficiency, regulators? | ( |
AMPK, AMP-activated protein kinase; ATP, Adenosine triphosphate; FAO, Fatty acid oxidation; G-CSF, Granulocyte-colony stimulating factor; Glut1, glucose transporter; G6P, glucose-6-phosphate; G6Pase-β, glucose-6-phosphatases- β; G6PD, glucose-6-phosphate dehydrogenase; G6PT, glucose-6-phosphate transporter; HIF-1α, Hypoxia-inducible factor-1α; mTOR, Mammalian target of rapamycin; mTORC1, Mammalian target of rapamycin complex 1; NADPH, reduced form of Nicotinamide adenine dinucleotide phosphate; NAMPT, Nicotinamide phosphor-ribosyltransferase; PiT1, Phosphate transporter 1; PPAR-γ, Peroxisome proliferator-activated receptor-gamma; PPP, Pentose phosphate pathway; ROS, Reactive oxygen species.